ArticleRenal failure2026
Serum BDNF and cognitive risk in maintenance hemodialysis: a machine learning study.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive impairment is common in maintenance hemodialysis, but practical risk-assessment tools remain limited. We evaluated the association between baseline serum brain-derived neurotrophic factor (BDNF) and 1-year screening-defined incident cognitive impairment and examined whether BDNF added predictive information beyond routine clinical, laboratory, and baseline cognitive variables. This single-center prospective cohort included 130 maintenance hemodialysis patients with baseline Montreal Cognitive Assessment (MoCA) scores ≥26. The primary outcome was screening-defined incident cognitive impairment, defined as follow-up MoCA <26. Serum BDNF was measured by enzyme-linked immunosorbent assay. Five models were assessed using repeated 5-fold cross-validation; repeated nested cross-validation was added as a sensitivity analysis. During follow-up, 70 patients (53.8%) met the screening-defined outcome. Each 1-SD higher BDNF level was associated with lower odds of the outcome [adjusted OR, 0.52 (95% CI, 0.34-0.80);
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.